CenterBook Partners LP Invests $671,000 in Krystal Biotech, Inc. (NASDAQ:KRYS)

CenterBook Partners LP acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,283 shares of the company's stock, valued at approximately $671,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC increased its stake in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after acquiring an additional 21,133 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Krystal Biotech by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock valued at $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Geode Capital Management LLC raised its stake in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Franklin Resources Inc. lifted its position in Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock valued at $43,774,000 after purchasing an additional 62,178 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Krystal Biotech by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 243,170 shares of the company's stock worth $38,095,000 after buying an additional 2,954 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

KRYS has been the subject of a number of recent analyst reports. HC Wainwright restated a "buy" rating and set a $221.00 price objective on shares of Krystal Biotech in a report on Friday, February 28th. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a research report on Thursday, February 20th. Chardan Capital raised their price objective on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price on the stock. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $220.00.

Krystal Biotech Price Performance

Krystal Biotech stock traded up $0.22 during trading hours on Tuesday, hitting $169.13. 165,479 shares of the stock traded hands, compared to its average volume of 295,024. The firm's 50 day moving average price is $174.09 and its 200-day moving average price is $172.15. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 56.57 and a beta of 0.75. Krystal Biotech, Inc. has a 1 year low of $141.72 and a 1 year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the prior year, the company earned $0.30 EPS. Krystal Biotech's quarterly revenue was up 116.4% on a year-over-year basis. Research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).